Introduction {#s0005}
============

Lung cancer is the leading cause of cancer-related death worldwide [@bb0005]. Non-small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, of which more than 70% are initially diagnosed with unresectable advanced disease [@bb0010], [@bb0015]. Systemic treatment, including molecular-targeted therapy, plays a central role in the clinical management of NSCLC.

Small-molecule tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, specifically target epidermal growth factor receptor (EGFR) and generate much optimism in the treatment of NSCLC. *EGFR* mutations have been demonstrated to be the strongest predictive biomarkers for the efficacy of EGFR-TKIs [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]. Patients with *EGFR* activating mutations, mainly in-frame deletions in exon 19 (19Del) and L858R substitutions in exon 21, have dramatic tumor responses and favorable survival benefit from EGFR-TKIs [@bb0045], [@bb0050]. However, most responsive patients would eventually experience progressive disease (PD). The secondary T790M mutation in exon 20 accounts for approximately 50% of the mechanism of acquired resistance [@bb0055]. Hence, it is of great clinical importance to analyze and track *EGFR* mutation status for predicting efficacy and monitoring resistance throughout EGFR-TKIs treatment in NSCLC patients.

*EGFR* mutation analysis is recommended in National Comprehensive Cancer Network clinical guidelines for NSCLC. Nevertheless, a national survey shows that only 9.6% of NSCLC patients with stage IIIb or IV disease had *EGFR*-related testing performed in China [@bb0060]. Partially because tumor tissue, the optimal DNA source for *EGFR* mutation analysis, is always difficult to obtain. Most NSCLC patients presenting inoperable advanced disease cannot provide surgical samples, whereas biopsy samples may not be sufficient for both pathologic examination and mutation analysis. Besides, many patients refuse repeated biopsy at the time of disease progression. However, peripheral blood of cancer patients frequently contains circulating free DNA (cfDNA) derived from tumor cells, which has been used to detect tumor-specific alterations [@bb0065]. Moreover, blood sampling is minimally invasive, readily accessible, relatively repeatable. Thus, using blood for *EGFR* mutation identification and follow-up shows promise.

Amplification Refractory Mutation System (ARMS) has been extensively used in large clinical trials, and has been proved to be a stable, highly sensitive and specific method for *EGFR* mutation detection in tumor tissue. This method was shown to be able to detect mutations in samples containing as little as 1% mutated DNA [@bb0020], [@bb0070], [@bb0075], [@bb0080]. In this study ARMS was used to detect *EGFR* mutations in plasma, serum and tumor tissue samples of NSCLC patients. The objective of this study was to determine the feasibility and predictive utility of *EGFR* mutation detection in blood.

Patients and Methods {#s0020}
====================

Patients {#s0025}
--------

To be eligible for this study, patients were required to have pathologically confirmed NSCLC and available plasma, serum or tumor tissue for *EGFR* mutation analysis. 164 patients were enrolled in this study from October 2011 to October 2012 at Shanghai Pulmonary Hospital. Patients' clinicopathologic characteristics, treatment regimens, tumor responses and survival outcomes were recorded. Smoking history was based on records at patients' first clinic visit and having smoked more than 100 cigarettes in a lifetime was used to define smokers. Performance status was evaluated using the Eastern Cooperative Oncology Group criteria. Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumours guidelines. Written informed consent was obtained from all participants, and provision of plasma, serum and tumor tissue for *EGFR* mutation analysis was optional. This study was approved by the Institutional Ethics Committee of Shanghai Pulmonary Hospital.

Sample Collection {#s0030}
-----------------

Plasma was collected from 141 patients and serum from 108 patients. Plasma/serum was separated from 4 mL peripheral blood by centrifugation at 1,000 rpm for 10 min at 4°C within 4 hours after collection and stored at -80°C until DNA extraction. Tumor tissue obtained from 142 patients via biopsy was put into RNAlater solution (Ambion, Austin, Texas, USA) and stored at -80°C until DNA extraction. All tumor tissue samples went through pathologic evaluation to confirm the diagnosis of NSCLC.

DNA Extraction {#s0035}
--------------

DNA was extracted from 1 ml plasma/serum or 2-20 mg tumor tissue. The DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) was used to extract DNA according to the manufacturer's instructions. The concentration and purity of DNA were determined by NanoDrop 2000 Spectrophotometer (Thermo Scientific, Waltham, USA). DNA extracted from tumor tissue was standardized to 1 ng/μL, whereas cfDNA extracted from plasma/serum was used for *EGFR* mutation analysis immediately without standardization.

EGFR Mutation Analysis {#s0040}
----------------------

The Human *EGFR* Gene Mutations Fluorescence Polymerase Chain Reaction Diagnostic Kit (Amoy Diagnostics, Xiamen, China), which is based on ARMS technology, was used to detect the 19Del, L858R and T790M mutation according to the manufacturer's instructions. Briefly, all reactions were performed in 25 μL volumes including 4.7 μL of template DNA, 0.3 μL of Taq polymerase and 20 μL of reaction buffer mix. Real-time PCR was carried out using MX3000P real-time PCR machine (Stratagene, La Jolla, CA, USA) under following conditions: (1) initial denaturation at 95°C for 5 min, (2) 15 cycles of 95°C 25 s, 64°C 20 s and 72°C 20 s, (3) 31 cycles of 93°C 25 s, 60°C 35 s and 72°C 20 s with fluorescence FAM and HEX reading at 60°C of each cycle in phase 3. Data analysis was performed with MxPro v4.10 (Stratagene, La Jolla, CA, USA). Cycle threshold (Ct) represents the threshold at which the signal was detected above background fluorescence. ΔCt values were calculated as the difference between the mutation Ct and control Ct. Positive results were defined as follows: (1) Ct is lower than 26, (2) Ct is higher than 26 and ΔCt is lower than the cut-off ΔCt value (11 for 19Del and L858R, 7 for T790M).

Statistical Analysis {#s0045}
--------------------

SPSS statistical software, version 17.0 (SPSS, Inc., Chicago, IL, USA) was used to analyze the data. The comparison of *EGFR* mutation rate among different sample types and the correlation between *EGFR* mutation status and clinicopathologic characteristics as well as response to EGFR-TKIs were evaluated using Chi-square test or Fisher's exact test. Cohen's kappa statistic and McNemar's test were used to analyze the concordance of *EGFR* mutation status between matched samples. Progression-free survival (PFS) with EGFR-TKIs treatment according to *EGFR* mutation status was estimated by Kaplan-Meier method and compared using log-rank test. A two-sided P value less than 0.05 indicated statistical significance.

Results {#s0010}
=======

Patient Characteristics {#s0050}
-----------------------

In total, 164 Chinese patients with NSCLC were enrolled in this study from October 2011 to October 2012 at Shanghai Pulmonary Hospital and their clinicopathologic characteristics are listed in [Table 1](#t0005){ref-type="table"}. During this study, 96 patients didn't receive EGFR-TKIs, 19 received EGFR-TKIs as first-line therapy, 32 as second-line therapy and 17 as third-line or subsequent therapy. Of 68 patients who received EGFR-TKIs, 51 had their samples collected before EGFR-TKIs treatment and 17 after PD to EGFR-TKIs.Table 1Patient Characteristics.CharacteristicsNo. of patients (n = 164)Percentage (%)Age (years) Median58 Range32-81Gender Female6841.5 Male9658.5Smoking history Never smoker8451.2 Smoker8048.8Histology Adenocarcinoma12878 Squamous cell carcinoma1811 Adenosquamous carcinoma53 NSCLC NOS138Stage IIIb148.5 IV13179.9 Postoperative relapse1911.6Performance Status 0-115192.1 295.5 3-442.4[^2]

EGFR Mutation Status {#s0055}
--------------------

A total of 141 plasma samples, 108 serum samples and 142 tumor tissue samples were available for *EGFR* mutation analysis ([Table 2](#t0010){ref-type="table"}). *EGFR* mutations were detected in 66 (46.5%) tumor tissue samples, of which 38 samples harbored a 19Del, 27 a L858R and 8 a T790M (concurrent with 19Del in 6 and L858R in one). 36 (25.5%) plasma samples exhibited *EGFR* mutations, including 22 with 19Del, 14 with L858R and 6 with T790M (concurrent with 19Del in 4 and L858R in one). One plasma sample exhibited both 19Del and L858R. In serum samples, *EGFR* mutation rate was 22.2%. 24 mutation-positive serum samples included 14 with 19Del, 9 with L858R and 3 with T790M (concurrent with 19Del in 2). *EGFR* mutation rate was significantly higher in tumor tissue than in plasma (46.5% versus 25.5%, P \< 0.001) and serum (46.5% versus 22.2%, P \< 0.001).Table 2*EGFR* Mutation Status.cfDNA *EGFR* mutation statusTumor *EGFR* mutation status19Del onlyL858R onlyT790M only19Del and T790ML858R and T790MWild typeUnknownTotalPlasma 19Del only1300201117 L858R only090011112 T790M only01000001 19Del and  L858R00000101 19Del and T790M10010024 L858R and T790M01000001 Wild type14121206115105 Unknown4401012223 Total32261617622164Serum 19Del only700301112 L858R only06001119 T790M only00000011 19Del and T790M10010002 Wild type1314020411484 Unknown11610032656 Total32261617622164[^3]

Correlation between EGFR Mutation Status and Clinicopathologic Characteristics {#s0060}
------------------------------------------------------------------------------

The correlation between *EGFR* mutation status and patients' clinicopathologic characteristics was summarized in [Table 3](#t0015){ref-type="table"}. In tumor tissue, *EGFR* mutation status was correlated with patients' gender, smoking history and histology. *EGFR* mutation rate was significantly higher in females than in males (60.0% versus 36.6%, P = 0.006), in never smokers than in smokers (55.4% versus 36.8%, P = 0.026) and in patients with adenocarcinoma than in those with other histology (53.7% versus 23.5%, P = 0.002). In blood samples, *EGFR* mutation status was only associated with histology. Patients with adenocarcinoma had significantly higher mutation rate than those with other histology in both plasma (30.0% versus 9.7%, P = 0.022) and serum (26.7% versus 4.5%, P = 0.024).Table 3Correlation between Clinical Characteristics and *EGFR* Mutation Status.CharacteristicTumor tissue (n = 142)Plasma (n = 141)Serum (n = 108)MutationWild typeP valuesMutationWild typeP valuesMutationWild typeP valuesAge0.3520.2690.133 ≥ 65 years1320627323 \< 65 years535630782161Gender0.0060.7900.877 Female362416441137 Male305220611347Smoking history0.0260.1360.108 Never413323521744 Current/former25431353740Histology0.0020.0220.024 Adenocarcinoma585033772363 Non-adenocarcinoma826328121Stage0.4450.8310.061 IIIb-IV606633952473 Postoperative replase610310011Performance Status0.7240.7291.000 0-1637134962276 ≥ 2352928[^4]

Comparison of EGFR Activating Mutation Status in Different Sample Types {#s0065}
-----------------------------------------------------------------------

→**Plasma versus Tumor Tissue***EGFR* mutation status was analyzed in 121 patients who provided plasma and matched tumor tissue samples ([Table 4](#t0020){ref-type="table"}). 89 patients had identical *EGFR* mutation status in both plasma and tumor tissue, including 27 with activating mutations and 62 with wild type. Discrepant mutation results were observed: 29 patients with mutant tumors had no mutation in matched plasma, whereas 3 patients with mutant cfDNA had no mutation in corresponding tumor tissue. The concordance rate of *EGFR* mutation status between plasma and tumor tissue was 73.6% (89/121). Compared with tumor tissue, the sensitivity and specificity for *EGFR* mutation detection in plasma by ARMS was 48.2% (27/56) and 95.4% (62/65), respectively. The false negative rate was high: 51.8% (29/56) of patients with *EGFR* mutant tumor were identified as wild type in plasma.Table 4Comparison of *EGFR* Activating Mutation Status in Different Sample Types.SampleTumor tissueTotalConcordance rateKappa coefficientMcNemar\'s testSensitivitySpecificityFalse positive rateFalse negative ratePPVNPVMutationWild typePlasma73.6%0.450(P \< 0.001)P \< 0.00148.2%95.4%4.6%51.8%90.0%68.1% Mutation27330 Wild type296291 Total5665121Serum66.3%0.342(P \< 0.001)P \< 0.00139.6%95.5%4.5%60.4%90.5%59.2% Mutation19221 Wild type294271 Total484492[^5]→**Serum versus Tumor Tissue**For *EGFR* mutation analysis 92 patients provided serum and matched tumor tissue samples ([Table 4](#t0020){ref-type="table"}). 61 patients exhibited identical *EGFR* mutation status in both serum and tumor tissue, including 19 with activating mutations and 42 with wild type. Discrepant results were observed: 29 patients with mutant tumors had no mutation in corresponding serum, whereas 2 patients with mutant cfDNA had no mutation in matched tumor tissue. The concordance rate of *EGFR* mutation status between serum and tumor tissue was 66.3% (61/92). Compared with tumor tissue, the sensitivity and specificity of *EGFR* mutation detection in serum by ARMS was 39.6% (19/48) and 95.5% (42/44), respectively. The false negative rate was high: 60.4% (29/48) of patients with *EGFR* mutant tumor were identified as wild type in serum.→**Plasma versus Serum**94 patients provided plasma and paired serum samples. 82 patients exhibited identical *EGFR* mutation status in both plasma and serum, including 17 with activating mutations and 65 with wild type. Discordant results were observed: 9 patients had mutant cfDNA in plasma but not in serum, whereas 3 patients had mutant cfDNA in serum but not in plasma. The concordance rate of *EGFR* mutation status between plasma and serum was 87.2% (82/94). The kappa coefficient of 0.657 was statistically significant (P \< 0.001), whereas the McNemar's test showed no significant difference (P = 0.146).

Comparison of *EGFR* T790M Mutation Status in Different Sample Types {#s0070}
--------------------------------------------------------------------

T790M was detected in 14 (8.5%) patients. Among them, one patient exhibited T790M concurrent with 19Del in matched plasma, serum and tumor tissue, whereas 10 patients had discrepant results between blood and tumor tissue.

Correlation between EGFR Mutation Status and Response to EGFR-TKIs {#s0075}
------------------------------------------------------------------

In 68 patients who received EGFR-TKIs, the correlation between *EGFR* mutation status and response to EGFR-TKIs was analyzed ([Table 5](#t0025){ref-type="table"}). For tumor tissue, objective response rate (ORR) of patients with or without *EGFR* activating mutations was 68.4% (26/38) and 10.5% (2/19), respectively (P \< 0.001). For plasma samples, ORR of patients with or without *EGFR* activating mutations was 68.4% (13/19) and 38.9% (14/36), respectively (P = 0.037). For serum samples, ORR of *EGFR* activating mutation positive and negative patients was 75.0% (12/16) and 39.5% (15/38), respectively (P = 0.017). ORR of patients with *EGFR* mutant tumor was consistent to that of patients with *EGFR* mutant cfDNA in plasma (P = 1.000) and serum (P = 0.751), whereas ORR of patients with wild-type tumor was significantly lower than that of patients with wild-type cfDNA in plasma (P = 0.028) and serum (P = 0.024).Table 5Correlation between *EGFR* Activating Mutation Status and Response To EGFR-TKIs.Sample*EGFR* activating mutation statusCR + PRSD + PDTotalTumor TissueMutation261238Wild type21719Total282957PlasmaMutation13619Wild type142236Total272855SerumMutation12416Wild type152338Total272754[^6]

Of 17 patients who provided samples after PD to EGFR-TKIs, 9 (52.9%) exhibited T790M concurrent with an *EGFR* activating mutation. In addition, one patient with L858R in tumor tissue but T790M in plasma before EGFR-TKIs treatment directly experienced PD after 1.4 months.

Correlation between EGFR Mutation Status and Survival {#s0080}
-----------------------------------------------------

The correlation between *EGFR* mutation status and median PFS time in patients treated with EGFR-TKIs was assessed. For tumor tissue, PFS for patients with or without *EGFR* activating mutations was 13.6 months (95% confidence interval \[CI\], 9.9 to 17.3) and 2.1 months (95% CI, 0.8 to 3.4), respectively. The difference was statistically significant (P \< 0.001, [Figure 1](#f0005){ref-type="fig"}*A*). For plasma samples, patients with *EGFR* activating mutations had a PFS of 7.9 months (95% CI, 1.6 to 14.1) compared with 6.1 months (95% CI, 2.7 to 9.6) for patients with wild-type *EGFR* (P = 0.953, [Figure 1](#f0005){ref-type="fig"}*B*). For serum samples, patients harboring *EGFR* activating mutations had a longer PFS of 7.9 months (95% CI, 6.5 to 9.2) than 5.7 months (95% CI, 2.1 to 9.2) for patients without mutations (P = 0.889, [Figure 1](#f0005){ref-type="fig"}*C*). Moreover, PFS of patients with *EGFR* mutant tumors was consistent to that of patients with *EGFR* mutant cfDNA in plasma (P = 0.094) and serum (P = 0.176), whereas PFS of patients with wild-type tumor was significantly shorter than that of patients with wild-type cfDNA in plasma (P = 0.023) and serum (P = 0.023).Figure 1Progression-free survival (PFS) curves for 68 patients treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A, PFS by *EGFR* activating mutation status in tumor tissue. B, PFS by *EGFR* activating mutation status in plasma. C, PFS by *EGFR* activating mutation status in serum. D, PFS by *EGFR* activating mutation status in both tumor tissue and blood samples. M+, positive for *EGFR* activating mutations; M-, negative for *EGFR* activating mutations.

Further, all 68 patients received EGFR-TKIs were stratified into 4 subgroups based on their mutational genotypes: (1) positive for *EGFR* activating mutations in both tumor tissue and blood (n = 20), (2) positive for *EGFR* activating mutations in tumor tissue but negative in blood (n = 18), (3) positive for *EGFR* activating mutations in blood but negative in tumor tissue (n = 4), and (4) negative for *EGFR* activating mutations in both tumor tissue and blood (n = 26). PFS for each group was graphed in [Figure 1](#f0005){ref-type="fig"}*D*. Patients in subgroup two had a favorable PFS of 19.7 months (95% CI, 11.5 to 28.0), compared with 11.0 months (95% CI, 3.1 to 19.0) of those in subgroup one (P = 0.102) and 1.7 (95% CI, 0.9 to 2.5) months of those in subgroup three (P \< 0.001). Patients in subgroup four had a comparable PFS of 2.3 months (95% CI, 0.3 to 4.3) with those in subgroup three (P = 0.508).

Discussion {#s0015}
==========

*EGFR* mutation analysis is recommended in clinical practice to direct personalized management for NSCLC patients. This study demonstrates the possibility of using blood to detect *EGFR* mutations, though tumor tissue remains the best sample.

The concordance of *EGFR* mutation status between blood and tumor tissue has been reported to be varying from 58.3% to 93.1%, with minimal false positive rate and variable false negative rate [@bb0085], [@bb0090], [@bb0095], [@bb0100], [@bb0105]. This study showed that compared with matched tumor tissue the concordance rate in plasma and serum was 73.6% and 66.3%, respectively. ARMS for *EGFR* mutation detection in cfDNA showed low sensitivity but high specificity. High specificity led to low false positive rate, suggesting that *EGFR* mutations identified in blood may be highly predictive of identical mutations in corresponding tumor. Low sensitivity caused high false negative rate, which was responsible for the significantly lower *EGFR* mutation rate in blood compared with tumor tissue. Thus, *EGFR* mutation-negative results in blood should be interpreted with caution as more than half of patients with *EGFR* mutant tumors were not detected in cfDNA by ARMS.

It is notable that 41 patients with mutant tumors had no detectable *EGFR* mutations in matched blood samples. This phenomenon has been observed in previous studies [@bb0090], [@bb0110], [@bb0115]. The trace amount and low percentage of mutant cfDNA could be below the detection limit of ARMS, giving rise to false negative results in blood. Another possible explanation is that prolonged storage of blood samples resulted in a decrease in the quantity of DNA extracted, thus affecting *EGFR* mutation detection [@bb0120]. In contrast, 5 patients with mutant cfDNA had no corresponding mutations in matched tumor tissue. This phenomenon has also been reported and could be explained by tumor heterogeneity: these biopsied tumor tissue samples may not carry the *EGFR* mutations detected in blood, because these mutations come from different parts of the tumor [@bb0125], [@bb0130], [@bb0135]. However, 4 of these 5 patients received EGFR-TKIs and had a comparable PFS with those who exhibited wild type in both blood and tumor tissue, suggesting that these mutations detected in blood could be false positive results.

There have been a limited number of studies on the correlation between *EGFR* mutation status in cfDNA and efficacy of EGFR-TKIs [@bb0140], [@bb0145], [@bb0150], [@bb0155], [@bb0160]. Though the researchers tend to agree that *EGFR* activating mutations in cfDNA may be predictive of better response to EGFR-TKIs, they are still uncertain whether *EGFR* mutation status in cfDNA can predict survival benefit from EGFR-TKIs. In a subgroup analysis of IPASS, ORR was 75.0% (18/24) and 27.1% (19/70) with gefitinib in patients with or without *EGFR* mutant cfDNA, respectively. PFS was significantly longer with gefitinib than carboplatin/paclitaxel in the cfDNA mutant subgroup (hazard ratio \[HR\], 0.29; 95% CI, 0.14-0.60; P \< 0.001) but not in the cfDNA wild-type subgroup (HR, 0.88; 95% CI, 0.61-1.28; P = 0.50) [@bb0110]. Xu et al. reported that an significant correlation between *EGFR* mutations status in plasma and tumor response to gefitinib was observed using ARMS but not denaturing high-performance liquid chromatography (DHPLC), whereas no association between *EGFR* mutation status in plasma and PFS or overall survival (OS) was observed no matter using ARMS or DHPLC [@bb0165]. Bai et al. detected *EGFR* mutations in plasma using DHPLC and found that about 62.2% of patients with *EGFR* mutations responded to gefitinib, whereas 37.8% of patients with wild-type *EGFR* also responded. They noted that patients with *EGFR* mutant cfDNA had a significantly longer PFS than those with wild-type cfDNA (11.1 months versus 5.9 months, P = 0.044), though no difference in OS was seen [@bb0125].

In the current study, patients with *EGFR* activating mutations in tumor tissue had significantly greater ORR and longer PFS with EGFR-TKIs, which accords with the finding of previous clinical trials [@bb0020], [@bb0025], [@bb0030], [@bb0035], [@bb0040]. Patients harboring *EGFR* activating mutations in cfDNA also had significantly higher ORR, which was consistent to that of patients with mutant tumors. In addition, patients with mutant cfDNA tended to have longer PFS than those with wild-type cfDNA, though the difference was not significant. These data suggest that *EGFR* activating mutations detected in blood may be predictive of improved tumor response and survival benefit from EGFR-TKIs. But patients with wild-type cfDNA had significantly higher ORR and longer PFS than those with wild-type tumors due to the presence of false negative results, suggesting that *EGFR* mutation-negative results detected in blood by ARMS is inferior to that in tumor tissue with respect to predicting clinical outcomes.

This study showed that in patients with *EGFR* mutant tumors those with wild-type cfDNA tended to have prolonged PFS compared with patients harboring corresponding mutant cfDNA. Similarly, a subgroup analysis of EURTAC indicated that in European patients with advanced *EGFR* mutation-positive NSCLC who received erlotinib as first-line therapy, the presence of mutant cfDNA in serum was associated with reduced PFS (HR, 0.48; 95% CI, 0.22-0.97; P = 0.04) and OS (HR, 0.46; 95% CI, 0.25-0.84; P = 0.02) [@bb0170]. For patients who provided pretreatment samples, the presence of *EGFR* mutations in blood may correlate with severe tumor burden, which contributes to higher proportion of tumor-derived cfDNA. Zhao et al. and Zhang et al. found that there were more detectable *EGFR* mutations in plasma from patients with advanced disease or patients with poorly differentiated tumors [@bb0105], [@bb0175]. Park et al. reported that tumor burden was predictive of inferior survival in NSCLC patients with *EGFR* mutant tumor who received gefitinib [@bb0180]. For patients who provided posttreatment samples, therapy-related *EGFR* mutation status shift from mutation to wild type may correlate with better response, thus affecting survival benefit. Yung et al. found that plasma concentrations of *EGFR* mutations could decline to undetectable level after EGFR-TKIs treatment in responsive patients [@bb0115]. Besides, Bai et al. reported that patients whose *EGFR* mutation status in cfDNA changed from mutant state to wild type after chemotherapy had significantly better clinical response [@bb0185]. Dowson et al. demonstrated that cfDNA could provide the earliest measure of treatment response [@bb0190]. Hence, serial changes of *EGFR* mutation status in cfDNA during follow-up period could be informative in monitoring treatment response and predicting survival benefit. However, novel ultrasensitive methods would be preferable, so that smaller changes in cfDNA mutation status can be monitored in a better way.

The secondary T790M mutation has been reported to be present in about half of NSCLC patients with acquired resistance to EGFR-TKIs and is usually concurrent with activating mutations, which is consistent with this study [@bb0195]. Rosell et al. and Su et al. reported that patients with T790M-positive tumors before EGFR-TKIs treatment had a shorter PFS than those having T790M-negative tumors [@bb0200], [@bb0205]. In this study one patient, with L858R in tumor tissue but T790M in plasma before EGFR-TKIs treatment, directly experienced PD after 1.4 months. Sakai et al. reported that when patients under 65 years who had partial response to EGFR-TKIs were grouped according to their T790M mutation status in plasma, patients with T790M had a significantly shorter PFS than patients without T790M [@bb0210]. These data suggest that T790M mutations in cfDNA may aid in monitoring resistance and predicting efficacy of EGFR-TKIs.

There were several limitations of this study. The sample size was relatively small and samples were not well matched. Besides, this study was not specifically designed to evaluate EGFR-TKIs treatment. Notwithstanding its limitations, this study demonstrates that *EGFR* mutations detected in blood of NSCLC patients by ARMS may be highly predictive of identical mutations in corresponding tumor, as well as showing correlations with tumor response and survival benefit from EGFR-TKIs. However, due to the method's low sensitivity in blood samples, tumor tissue remains the best sample for *EGFR* mutation analysis. Further investigations involving appropriate methodologies to decrease false negatives in cfDNA-based *EGFR* mutation analysis are warranted.
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